Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up.
Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [(123)I] β-CIT SPECT scans were acquired. The percent change in [(123)I] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects.
Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [(123)I] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects.
Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035714 | PMC |
| http://dx.doi.org/10.1212/WNL.0000000000000424 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Levo-Stepholidine as a Potential Cognitive Enhancer: Insights into Executive Function and Memory Improvements.
Biomedicines
November 2024
State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China.
Background/objectives: Levo-Stepholidine (-SPD), a compound extracted from Chinese herbs, has the potential to treat psychotic disorders where cognitive deficits are a critical challenge. -SPD displays a D1R agonism/D2R antagonism pharmacological profile, and its effect on cognitive function is still vague and lacks comprehensive study. Here, we investigated the impact of l-SPD on two core indexes of executive function, working memory and response inhibition, and learning and memory.
View Article and Find Full Text PDFWe examined DA activity in the medial prefrontal cortex (mPFC) and nucleus accumbens core (NAcc) in two Different Rat Models of Attention-Deficit/Hyperactivity Disorder: Spontaneously Hypertensive Rats (SHR) Versus Lphn3 Knockout Rats. We examined baseline stimulation-evoked phasic DA release, half-life, and DA autoreceptor (DAR) functioning in the mPFC and NAcc, as well as the response to nomifensine (10 mg/kg, IP), a DA transporter (DAT) blocker, on these measures in the NAcc. Both rat models were hypodopaminergic, with notable regional and mechanistic differences.
View Article and Find Full Text PDFBacopaside-I ameliorates motor dysfunction and neurodegeneration in rat model of Parkinson's disease.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Biochemistry, King George's Medical University, Lucknow, India.
Article Synopsis
- Chronic administration of Bacopa monnieri extract shows potential neuroprotective effects in animal models of neurodegenerative disorders, including Parkinson's and Alzheimer's diseases.
- The study specifically tested Bacopaside-I (BS-I), highlighting its ability to improve motor function and reverse dopamine depletion caused by rotenone, a chemical used to induce Parkinson's-like symptoms in rats.
- Findings suggest that BS-I increases key genetic markers and the number of dopamine-producing neurons, establishing its potential as a basis for future drug development against Parkinson’s disease.
Epigenomic and clinical analyses of striatal DAT binding in healthy individuals reveal well-known loci of Parkinson's disease.
Heliyon
December 2024
Experimental Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Striatal dopamine transporter (DAT) binding is a sensitive and specific endophenotype for detecting dopaminergic deficits across Parkinson's disease (PD) spectrum. Molecular and clinical signatures of PD in asymptomatic phases help understand the earliest pathophysiological mechanisms underlying the disease. We aimed to investigate whether blood epigenetic markers are associated with inter-individual variation of striatal DAT binding among healthy elderly individuals.
View Article and Find Full Text PDFAberrant extracellular dopamine clearance in the prefrontal cortex exhibits ADHD-like behavior in NCX3 heterozygous mice.
FEBS J
January 2025
Research Center for Pharmaceutical Development, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Article Synopsis
- ADHD is linked to dopaminergic dysfunction in the prefrontal cortex, leading to symptoms like hyperactivity, inattention, and cognitive deficits.
- Researchers identified sodium-calcium exchanger 3 (NCX3) in dopaminergic neurons, finding that its knockdown causes abnormal dopamine influx and related behavioral issues in mice.
- NCX3 heterozygous mice display ADHD-like behaviors, such as hyperactivity and cognitive deficits, which can be improved with methylphenidate, highlighting the role of NCX3 in dopamine signaling and ADHD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!